PAVmed, Inc.

PAVmed, Inc. is a commercial-stage, diversified medical technology company focused on developing innovative diagnostics and digital health solutions. The company operates through two primary business units: Lucid Diagnostics and Veris Health. Lucid Diagnostics commercializes EsoGuard®, the first and only diagnostic test for detecting esophageal precancer and cancer, delivered via both traditional clinical settings and mobile test units. Veris Health develops a digital health platform and connected health devices for enhanced personalized cancer care through remote patient monitoring. PAVmed operates a shared-services business model that enables economies of scale across its subsidiaries. The company demonstrates clinical commitment through partnerships including participation in CancerX, a public-private partnership co-hosted by Moffitt Cancer Center and the Digital Medicine Society. Products are positioned for healthcare systems, clinicians, and patients across device, diagnostics, and digital health sectors. Recent press activity indicates ongoing expansion of medical device portfolio and continued commercialization efforts. The company maintains investor relations presence and actively engages in disease awareness initiatives such as firefighter screening programs for esophageal precancer detection.